Iterum Therapeutics (NASDAQ:ITRM) Stock Rating Upgraded by HC Wainwright

Iterum Therapeutics (NASDAQ:ITRMGet Free Report) was upgraded by equities researchers at HC Wainwright from a “neutral” rating to a “buy” rating in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage currently has a $6.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 277.36% from the company’s current price. HC Wainwright also issued estimates for Iterum Therapeutics’ FY2028 earnings at $0.16 EPS.

Iterum Therapeutics Trading Down 3.6 %

NASDAQ ITRM opened at $1.59 on Wednesday. The company’s fifty day moving average price is $1.80 and its two-hundred day moving average price is $1.25. The company has a debt-to-equity ratio of 3.63, a current ratio of 2.35 and a quick ratio of 2.35. Iterum Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.50. The company has a market capitalization of $21.37 million, a price-to-earnings ratio of -0.65 and a beta of 2.41.

Iterum Therapeutics (NASDAQ:ITRMGet Free Report) last posted its quarterly earnings results on Tuesday, November 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.61. As a group, research analysts predict that Iterum Therapeutics will post -2.93 earnings per share for the current fiscal year.

Insider Transactions at Iterum Therapeutics

In other news, Director Michael W. Dunne acquired 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The shares were acquired at an average price of $1.40 per share, with a total value of $35,000.00. Following the acquisition, the director now directly owns 113,754 shares in the company, valued at $159,255.60. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other news, Director Michael W. Dunne acquired 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were acquired at an average price of $2.03 per share, with a total value of $40,600.00. Following the acquisition, the director now directly owns 78,754 shares in the company, valued at $159,870.62. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Michael W. Dunne acquired 25,000 shares of the company’s stock in a transaction that occurred on Friday, December 22nd. The stock was purchased at an average cost of $1.40 per share, for a total transaction of $35,000.00. Following the acquisition, the director now owns 113,754 shares in the company, valued at $159,255.60. The disclosure for this purchase can be found here. In the last three months, insiders have acquired 55,000 shares of company stock worth $91,500. 5.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Iterum Therapeutics

Several large investors have recently bought and sold shares of the stock. Apollon Wealth Management LLC acquired a new position in Iterum Therapeutics during the 2nd quarter valued at about $214,000. Dimensional Fund Advisors LP acquired a new position in Iterum Therapeutics during the 3rd quarter valued at about $101,000. Goldman Sachs Group Inc. acquired a new position in Iterum Therapeutics during the 2nd quarter valued at about $61,000. Finally, Renaissance Technologies LLC increased its stake in Iterum Therapeutics by 199.1% during the 2nd quarter. Renaissance Technologies LLC now owns 323,300 shares of the company’s stock valued at $65,000 after buying an additional 215,200 shares during the period. Institutional investors and hedge funds own 3.39% of the company’s stock.

Iterum Therapeutics Company Profile

(Get Free Report)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections.

Featured Stories

Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.